We publish only what we can stand behind. This page documents our security posture, every claim we make publicly, and — just as importantly — what we deliberately do not claim.
Corterve is a product of MannaSync Solutions Inc. It helps patients find clinical trials that may be relevant, and helps research sites and sponsors reach those patients. It does not determine eligibility and does not promise an enrollment outcome.
Security practices aligned with HIPAA requirements for protecting health information. Code evidence — not a certification of operating effectiveness.
Patient health information is encrypted at rest and in transit. Encryption is applied at the storage layer.
We do not share patient data without explicit consent. Patients must consent before any data is shared with a research team.
Each claim below is active, reviewed on the date shown, and supported by the evidence type listed. Code evidence is labeled as code evidence — never as certification or operating effectiveness.
“Corterve is free for patients — trial discovery, matching, and browsing.”
Scope
All patient-facing features: trial search, assessment, matching, alerts, trial browsing.
Evidence
CONSUMER_PREMIUM_ENABLED=false — checkout endpoint returns 410 Gone. See backend checkout configuration.
Appears on
/pricing, /assessment, /trials, homepage
Review date
2026-10-25
“Patient health information is encrypted at rest and in transit.”
Scope
All patient-submitted health data stored in Corterve systems.
Evidence
Code evidence: encryption applied at the storage layer. This is code evidence, not a certification of operating effectiveness.
Appears on
/trust, homepage, /assessment
Review date
2026-10-01
“We do not share patient data without explicit consent.”
Scope
All patient data sharing with research sites or sponsors.
Evidence
Privacy policy and consent flow — patient must explicitly consent before any data is shared with a research team.
Appears on
/trust, homepage, /assessment
Review date
2026-10-01
“We never charge per patient, per referral, or per enrollment.”
Scope
All commercial relationships with sponsors and sites.
Evidence
Commercial pricing policy — no per-patient, per-referral, or per-enrollment fees.
Appears on
/community, /services, /for-sites, /for-sites/study-acquisition, /for-sites/patient-acquisition, /sponsors
Review date
2026-10-01
“Corterve does not determine eligibility and does not promise an enrollment outcome.”
Scope
All patient matching and trial discovery features.
Evidence
Product design: Corterve surfaces potentially relevant trials; the research team at each site makes the actual eligibility determination.
Appears on
/contact, /trust, /assessment, /, /for-sites, /for-sites/patient-acquisition, /for-sites/study-acquisition
Review date
2026-10-01
“Lean sites come to Corterve for study finding, participant finding, or both. Community engagement remains available for sponsors and CROs. Design support is an optional add-on.”
Scope
All public-facing commercial pages.
Evidence
Public site IA: /for-sites and its acquisition pages are the site offers; /sponsors is the sponsor/CRO landing; /services is the sponsor catalog; /for-organizations and /community are thin routers. /community/sponsor and /community/site redirect into those funnels.
Appears on
/, /for-sites, /for-sites/study-acquisition, /for-sites/patient-acquisition, /for-organizations, /contact, /services, /sponsors
Review date
2026-11-10
Transparency means being clear about what we don't say, not just what we do. The following are topics where we deliberately do not make public claims.
We do not display invented certifications, compliance badges, or seals — including “21 CFR Part 11 Compatible” and “GDPR Ready.” We describe what our code does, not what an auditor has certified.
We do not claim that Community Connect or any Corterve service accelerates enrollment by any specific percentage. Outreach is a strategy, not a guarantee.
We do not award studies or select sites. We take on study finding; sponsors and CROs still decide the award.
We do not claim that people who screen-fail will join a site’s practice, or that every introduction creates operational value. Care after a study conversation is the person’s choice and requires separate consent.
We do not claim that our outreach lowers placebo response, improves treatment signal, or produces a measurable enrollment outcome.
We do not sell or describe proprietary architecture, match scores, activation engines, or other internal machinery on public pages. Public copy describes the finding work we take on.
We do not publish invented enrollment percentages, sample report numbers, ROI models, or case-study quotes that imply a guaranteed outcome.
The published site license is $99/month. Custom sponsor/CRO programmes are scoped with us. We do not publish unpublished SKUs or volume discounts.
We do not describe our platform as "AI-powered." We connect patients to relevant trials based on their health profile and location.
We do not claim to pre-screen patients. We surface trials that may be relevant; the research team determines eligibility.
We do not claim 24/7 support availability. Our contact routes are monitored during business hours.
We do not publicly advertise a BAA. Business associate arrangements are discussed directly with the relevant party.
We do not make public claims about de-identification methods or guarantees.
We do not publicly claim penetration test results or security audit outcomes.
We do not publish a public API catalog, sample demand scores, feasibility scores, enrollment-time estimates, or unpublished partner SLAs. Integrations are scoped with us.
We do not claim affiliation with Harvard Medical School, NIH, FDA, or other institutions. Editorial sources are cited per article, not as an implied endorsement.
We say patient access is free. We do not say "free forever" — we cannot guarantee the indefinite future of any business.
Public marketing, legal, discovery, contact, and partner-integration pages on corterve.com. Finding work only — no award, eligibility determination, enrollment, placebo, unpublished-price, public-API-score, or BAA-as-product claims. Signed 2026-09-18.
